What is CRDF's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.08B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CRDF?

P/E (TTM) is n/a and 52-week range is $0.76 to $3.31 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CRDF figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CRDF?

The company profile lists revenue (TTM) near $576K, net income (TTM) near $-4.54B, EPS (TTM) near $-0.59 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cardiff Oncology Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 77.8M shares outstanding, ISIN US14147L1089 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Cardiff Oncology Inc

$CRDF

Health Care · Biotechnology

IR Run Scenarios

$1.08

+1.89%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2004-07-27. The firm's lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor being evaluated in a Phase II trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). The firm's clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.

Employees

Website

cardiffoncology.com/

IPO

2004-07-27

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)